PET2‐Adapted Therapy in Patients With Advanced‐Stage Hodgkin Lymphoma Treated With Frontline ABVD: Searching for the Baby in the Bathwater

Documenti analoghi

• 732 | EXTENDED BRENTUXIMAB VEDOTIN LEAD‐IN AND ABBREVIATED AVD IN OLDER PATIENTS (> 60 YEARS) WITH ADVANCED HODGKIN LYMPHOMA AND HIGH COMORBIDITY (ECOG ≥ 2 AND/OR CIRS‐G > 10)
  di: M. Bonanni, et al.
  Pubblicazione: (2025)
• Liposomal Doxorubicin, Vinblastine and Dacarbazine Plus Consolidation Radiotherapy of Residual Nodal Masses for Frontline Treatment in Older Adults With Advanced Stage Classic Hodgkin Lymphoma: Improved Outcome in a Multi‐Center Real‐Life Study
  di: M. Picardi, et al.
  Pubblicazione: (2024)
• International Cost‐Effectiveness Analysis of Nivolumab Versus Brentuximab Vedotin for Patients With Advanced‐Stage Classic Hodgkin's Lymphoma
  di: Youwen Zhu, et al.
  Pubblicazione: (2026)
• Efficacy of escalating therapy with brentuximab vedotin‐AVD in advanced stage Hodgkin lymphoma patients with positive interim positron emission tomography after ABVD
  di: Carmen Martínez, et al.
  Pubblicazione: (2024)
• Correction to “Defining and Addressing the Current Unmet Medical Needs for the Frontline Treatment of Advanced Stage Aggressive Large B‐Cell Lymphoma: A Perspective From an Ad Hoc Panel of Italian Experts”
  Pubblicazione: (2025)